Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

2(40.0%)

Phase 2

1(20.0%)

Phase 4

1(20.0%)

N/A

1(20.0%)

5Total

Phase 3(2)

Phase 2(1)

Phase 4(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03719287Completed

Study to Estimate the Point Prevalence of Peripheral Intravenous Catheter-related Complications in Brazil

Role: collaborator

NCT03391960Not ApplicableCompleted

Passive Disinfection Cap Compliance Study

Role: collaborator

NCT02856919Phase 4Completed

A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel in Patients With Chronic Persistent Vascular Facial Erythema.

Role: collaborator

NCT02907320Phase 2Withdrawn

EXPLORATORY ASSESSMENT OF THE EFFECTS OF CYCLO 3 ® FORT (Ruscus Extract, Hesperidin Methyl Chalcone, Ascorbic Acid) OR MICRONISED PURIFIED FLAVONOID FRACTION ON VASCULAR PARAMETERS AND BIOMARKERS IN WOMEN SUFFERING FROM CHRONIC VENOUS DISEASE (CEAP C2 OR C3), OVER 8 WEEKS

Role: collaborator

NCT02448199Phase 3Unknown

Study of Association of Anti-inflammatory and Anti-rheumatic

Role: collaborator

NCT01324934Phase 3Terminated

Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids

Role: collaborator

NCT01190124Completed

Raltegravir With Optimized Background Therapy (OBT) in Multiple Experienced HIV-infected Patients

Role: collaborator

All 7 trials loaded